+1 - Solvay

More documents

Recommendations

Info

8 Strategic Positions of Solvay Sales: EUR 9.6 billion – REBIT: EUR 1.2 billion 28 340 employees Pharmaceuticals Main products Europe N. America World Fibrates 1 1 1 Antivertigo 1 1 1 Pancreatic enzymes 1 1 1 Antispasmodics/ irritable bowel syndrome 1 1 1 Female hormone treatment 3 2 2 Male hormone treatment 3 1 1 Chemicals Main products Europe World Soda ash 1 1 Hydrogen peroxide 1 1 Sodium percarbonate/perborate 1 1 Caustic soda 2 3 Precipitated calcium carbonate amongst the world leaders Sodium bicarbonate 1 1 Plastics Main products Europe World Fluorinated polymers 1 3 Other Specialty Polymers amongst the world leaders Inergy Automotive Systems (fuel systems) 1 1 Vinyls 2 3 Pipelife (tubes and fittings) leader in its markets Pharmaceuticals Sales: EUR 2.6 billion – REBIT: EUR 457 million 9 178 employees Therapeutic fields Integrated franchises (R&D and commercial) • Cardiometabolics (dyslipidemia, obesity, type 2 diabetes, congestive heart failure, renal insufficiency, atrial fibrillation); • Neuroscience (schizophrenia, Parkinson’s disease, traumatic brain injury, cognition); • Niches in flu vaccines and pancreatic enzymes. Commercial franchises • Gastroenterology; • Women’s and men’s health. Strategic priorities (2010) • Concentration on therapeutic fields; • Improving profitability: – Operating margin*: 20%; – Efficiency improvements: EUR 300 million of annual savings; • Sales: EUR 3.2 billion; • Increasing the R&D/sales ratio. * REBIT/sales Mercosur Geographic Deployment and • Expansion under way in vinyls, including bioethanol-based products • Development of Specialty Polymers and Inergy Solvay Global Annual Report 2007
Strategic Positions of Solvay Chemicals Sales: EUR 3.0 billion – REBIT: EUR 345 million 8 395 employees 4 clusters Minerals • Soda ash and derivatives (bicarbonate); • Advanced Functional Minerals (precipitated calcium carbonate). Electrochemistry, fluorinated products • Electrochemicals and derivatives (caustic soda, epichlorohydrin); • Fluorinated products. Oxygen • Hydrogen peroxide; • Detergents (persalts). Organic (Molecular Solutions) Strategic priorities • Intensifying our geographic expansion; • Pursuing technological innovation; • Growth in specialties (mainly bicarbonate and fluorinated and organic specialties); • Competitiveness. Technological Innovation Platforms Plastics Sales: EUR 4.0 billion – REBIT: EUR 441 million 8 977 employees 2 clusters Specialties • Specialty Polymers (high and ultra-high performance polymers like fluorinated polymers, elastomers and fluids, barrier materials, polyarylamides, polysulfones, high performance polyamides, liquid crystal polymers); • Inergy Automotive Systems (50/50 joint venture with Plastic Omnium). Vinyls • Vinyls (integrated electrolysis chain, VCM (monomer), PVC (polymer) and PVC compounds); • Pipelife (50/50 joint venture with Wienerberger). Strategic priorities • Globalization; • R&D and technological innovation; • Product leadership; • Competitiveness. Asia • Thailand: expansion under way in vinyls, new investments (epichlorohydrin (Epicerol ® ), Inergy, hydrogen peroxide) • India: Specialty Polymers, Pharma, Inergy • China: ultra-pure H 2 O 2 , Specialty Polymers, Pharma, Inergy • South Korea: Fluor Our Positions 9 Russia/CIS • Pharma: major sales growth over past 5 years • Major industrial project in vinyls (RusVinyl) • JV in vinyl compounds • Pipelife & Inergy Solvay Global Annuaal Report 2007
Page 1 and 2: Ready for tomorrow Growth, Competit
Page 3 and 4: Key figures - Solvay Group Financia
Page 5 and 6: 2007 Highlights February Perfluorop
Page 7 and 8: Strategy Strategy of sustainable an
Page 9 and 10: Mission, Vision, Values Solvay is a
Page 11: Chairmen’s message Resources area
Page 15 and 16: Financial Statements part 1 Record
Page 17 and 18: Management Report EUR million 2006
Page 19 and 20: Management Report Capital expenditu
Page 21 and 22: Information for Shareholders Curren
Page 23 and 24: Pharmaceuticals Sector Joachim Adam
Page 25 and 26: Pharmaceuticals Sector Driving our
Page 27 and 28: Pharmaceuticals Sector Results in 2
Page 29 and 30: Pharmaceuticals Sector Suzanne Hatt
Page 31 and 32: Pharmaceuticals Sector Wolgang Kalb
Page 33 and 34: Pharmaceuticals Sector Research and
Page 35 and 36: Chemicals Sector On the path of gro
Page 37 and 38: Chemicals Sector Driving our strate
Page 39 and 40: Chemicals Sector expansions were su
Page 41 and 42: Chemicals Sector Chemicals 37 Ricca
Page 43 and 44: Chemicals Sector The “Organic”
Page 45 and 46: Plastics Sector Plastics 41 Our str
Page 47 and 48: Plastics Sector Driving our strateg
Page 49 and 50: Plastics Sector SOLVERA ® and FLUO
Page 51 and 52: Plastics Sector Despite considerabl
Page 53 and 54: Plastics Sector Dominique Marchand
Page 55 and 56: New Business Development Thierry De
Page 57 and 58: New Business Development organized
Page 59 and 60: Partnership Since 2004, Solvay has
Page 61 and 62: Sustainable Development The most im
Page 63 and 64:
Sustainable Development The new riv
Page 65 and 66:
Human Resources During the June 200
Page 67 and 68:
Human Resources They are also the
Page 69 and 70:
Financial Financial Statements The
Page 71 and 72:
Financial Goodwill EUR Million Note
Page 73 and 74:
Financial Fair value differences Th
Page 75 and 76:
Financial • IFRIC 14 IAS 19 The L
Page 77 and 78:
Financial • the assets will gener
Page 79 and 80:
Financial Notes to the financial st
Page 81 and 82:
Financial (2) Financial data by reg
Page 83 and 84:
Financial The EUR 123 million of as
Page 85 and 86:
Financial (12b) Deferred taxes on t
Page 87 and 88:
Financial (19) Acquisition / sale o
Page 89 and 90:
Financial The 3-year vesting period
Page 91 and 92:
Financial (23) Goodwill EUR Million
Page 93 and 94:
Financial Finance leases EUR Millio
Page 95 and 96:
Financial The table below shows the
Page 97 and 98:
Financial The amounts recorded in t
Page 99 and 100:
Financial Actuarial assumptions use
Page 101 and 102:
Financial The amount of the provisi
Page 103 and 104:
Financial Cash and cash equivalents
Page 105 and 106:
Financial Managing the transactiona
Page 107 and 108:
Financial Financial instruments IAS
Page 109 and 110:
Financial (32) Contingent liabiliti
Page 111 and 112:
Financial 1. Market & Growth - Stra
Page 113 and 114:
Financial To manage legal risk Solv
Page 115 and 116:
Financial • Product Development R
Page 117 and 118:
Financial 2007 Consolidation Scope
Page 119 and 120:
Financial List of fully consolidate
Page 121 and 122:
Financial Solvay Healthcare Ltd, So
Page 123 and 124:
Financial List of proportionately c
Page 125 and 126:
Financial ARGENTINA Inergy Automoti
Page 127 and 128:
Financial Income statement of Solva
Page 129 and 130:
Financial Additional comment The pr
Page 131 and 132:
Corporate Governance Report on the
Page 133 and 134:
Corporate Governance Introduction T
Page 135 and 136:
Corporate Governance June 2005 for
Page 137 and 138:
Corporate Governance certainty the
Page 139 and 140:
Corporate Governance Year of birth
Page 141 and 142:
Corporate Governance which could po
Page 143 and 144:
Corporate Governance attendance fee
Page 145 and 146:
Corporate Governance They are not s
Page 147 and 148:
Corporate Governance renewal of the
Page 149 and 150:
Corporate Governance The Solvay sha
Page 151 and 152:
Corporate Governance ANNEXE 2 COMPE
Page 153 and 154:
“… I have always sought to serv
Page 155 and 156:
Board of Directors 1. Mr. Aloïs Mi
Page 157 and 158:
Executive Committee and General Man
Page 159 and 160:
Financial Glossary ABAF: Belgian Fi
Page 161 and 162:
Shareholders’ Diary - Tuesday May
show all

+1 - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?